CRISPR–Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl adolygu › adolygiad gan gymheiriaid
StandardStandard
Yn: Nature Reviews Urology, Cyfrol 21, 01.07.2024, t. 1-11.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl adolygu › adolygiad gan gymheiriaid
HarvardHarvard
APA
CBE
MLA
VancouverVancouver
Author
RIS
TY - JOUR
T1 - CRISPR–Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer
AU - Smith, Danielle
AU - Lunj, Sapna
AU - Adamson, Anthony
AU - Nagarajan, Sankari
AU - Smith, Tim
AU - Reeves, Kim
AU - Hoskin, Peter
AU - Choudhury, Ananya
PY - 2024/7/1
Y1 - 2024/7/1
N2 - Gene editing technologies help identify the genetic perturbationsdriving tumour initiation, growth, metastasis and resistance totherapeutics. This wealth of information highlights tumour complexityand is driving cancer research towards precision medicine approachesbased on an individual’s tumour genetics. Bladder cancer is the11th most common cancer in the UK, with high rates of relapse andlow survival rates in patients with muscle-invasive bladder cancer(MIBC). MIBC is highly heterogeneous and encompasses multiplemolecular subtypes, each with diferent responses to therapeutics.This evidence highlights the need to identify innovative therapeutictargets to address the challenges posed by this heterogeneity. CRISPR–Cas9 technologies have been used to advance our understanding ofMIBC and determine novel drug targets through the identifcationof drug resistance mechanisms, targetable cell-cycle regulators, andnovel tumour suppressor and oncogenes. However, the use of thesetechnologies in the clinic remains a substantial challenge and willrequire careful consideration of dosage, safety and ethics. CRISPR–Cas9 ofers considerable potential for revolutionizing bladder cancertherapies, but substantial research is required for validation beforethese technologies can be used in the clinical setting.
AB - Gene editing technologies help identify the genetic perturbationsdriving tumour initiation, growth, metastasis and resistance totherapeutics. This wealth of information highlights tumour complexityand is driving cancer research towards precision medicine approachesbased on an individual’s tumour genetics. Bladder cancer is the11th most common cancer in the UK, with high rates of relapse andlow survival rates in patients with muscle-invasive bladder cancer(MIBC). MIBC is highly heterogeneous and encompasses multiplemolecular subtypes, each with diferent responses to therapeutics.This evidence highlights the need to identify innovative therapeutictargets to address the challenges posed by this heterogeneity. CRISPR–Cas9 technologies have been used to advance our understanding ofMIBC and determine novel drug targets through the identifcationof drug resistance mechanisms, targetable cell-cycle regulators, andnovel tumour suppressor and oncogenes. However, the use of thesetechnologies in the clinic remains a substantial challenge and willrequire careful consideration of dosage, safety and ethics. CRISPR–Cas9 ofers considerable potential for revolutionizing bladder cancertherapies, but substantial research is required for validation beforethese technologies can be used in the clinical setting.
U2 - 10.1038/s41585-024-00901-y
DO - 10.1038/s41585-024-00901-y
M3 - Review article
VL - 21
SP - 1
EP - 11
JO - Nature Reviews Urology
JF - Nature Reviews Urology
SN - 1759-4820
ER -